Preclinical News and Research

RSS

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.

18 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

Retrovirox receives another NIH grant for novel inhibitors of HIV entry

RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.

12 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Oxygen nanosensor could improve tumor imaging

A new material developed at the University of Virginia - an oxygen nanosensor that couples a light-emitting dye with a biopolymer - simplifies the imaging of oxygen-deficient regions of tumors. Such tumors are associated with increased cancer aggressiveness and are particularly difficult to treat.

11 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Innexus Biotechnology announces business development initiative on lead preclinical candidate

InNexus Biotechnology Inc. announced today that the Company will embark on a business development initiative for DXL625™ (CD20), the Company’s lead preclinical candidate for the prospective treatment of Non-Hodgkin’s Lymphoma and/or Chronic Lymphocytic Leukemia.

6 Aug 2009

Innovative diabetes drug discovery partnership

The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform.

5 Aug 2009

Cancer Therapy & Research Center (CTRC) retains status as NCI-designated cancer center

The National Cancer Institute, the nation’s top cancer research organization, has renewed the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio as one of its NCI-designated Cancer Centers for three years. The distinction comes with $5.4 million in new federal funding through 2012 to sustain and grow the cancer center’s rapidly expanding research programs, now consisting of 140 scientists at work on a multitude of cancer projects.

4 Aug 2009

Accelerating the development of new cancer drugs

A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd.

4 Aug 2009

New nano-gene therapy technique could fight late-stage tumors

Tiny particles carrying a killer gene can effectively suppress ovarian tumor growth in mice, according to a team of researchers from MIT and the Lankenau Institute.

31 Jul 2009

Covance enters strategic genomic services agreement with Merck

Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.

30 Jul 2009

New drug promises to reduce damage from a heart attack

Research into a new drug by Australian heart experts has found that it can dramatically reduce heart muscle damage after a heart attack.

28 Jul 2009

Artificial intelligence used to diagnose metastatic cancer

When doctors are managing care for women with breast cancer, the information available to them profoundly influences the type of care they recommend. Knowing whether a woman's cancer has metastasized, for instance, directly affects how her doctors will approach treatment -- which may in turn influence the outcome of that treatment.

28 Jul 2009

Nanodiamonds hold promise for wound-healing applications

Bacterial infection is a major health threat to patients with severe burns and other kinds of serious wounds such as traumatic bone fractures. Recent studies have identified an important new weapon for fighting infection and healing wounds: insulin.

27 Jul 2009

Growth factor enhances heart regeneration, improves heart function without need for cardiac stem cells

Injured heart tissue normally can't regrow, but researchers at Children's Hospital Boston have now laid the groundwork for regenerating heart tissue after a heart attack, in patients with heart failure, or in children with congenital heart defects.

24 Jul 2009

Johns Hopkins-designed animal tuberculosis "tracker" to speed drug and vaccine studies

Johns Hopkins researchers have developed a novel way to monitor in real time the behavior of the TB bacterium in mouse lungs noninvasively pinpointing the exact location of Mycobacterium tuberculosis. The new monitoring system is expected to speed up what is currently a slow and cumbersome process to test the safety and efficacy of various TB drug regimens and vaccines in animals. Plans are already under way for developing a similar system to monitor TB disease in humans.

23 Jul 2009